{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:16Z","timestamp":1792123096265,"version":"4.4.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease associated with multisystem comorbidities and impaired mental health. The lesions are typically characterized by sharply demarcated, erythematous plaques covered with silvery scales. Treatment options include topical agents, phototherapy, systemic therapies, and biologic agents. Traditional systemic treatments are generally contraindicated in patients with cancer due to their immunosuppressive effects. Although biologics are widely used in the management of psoriasis, their safety in patients with malignancy remains insufficiently evaluated, as individuals with cancer are typically excluded from clinical trials due to concerns about cancer progression. We report the case of a 61-year-old man whose psoriasis markedly worsened following treatment with sintilimab for pulmonary metastases secondary to colon cancer. The patient was successfully treated with guselkumab, an interleukin (IL)-23 inhibitor, resulting in significant improvement in psoriasis symptoms, while the pulmonary condition remained stable during follow-up after completion of standard cancer therapy. This case highlights the potential utility of IL-23 inhibitors as safe and effective treatment options for patients with concomitant psoriasis and malignancy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1573495","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:34Z","timestamp":1750392634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient"],"prefix":"10.3389","volume":"16","author":[{"given":"Jianhao","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200757119","article-title":"Antibody-mediated blockade of the IL23 receptor destabilizes intratumoral regulatory T cells and enhances immunotherapy","volume":"119","author":"Wight","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3994","article-title":"Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases","volume":"71","author":"Teng","year":"2011","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1646","article-title":"Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases","volume":"74","author":"von Scheidt","year":"2014","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor\u2013related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.09.003","article-title":"Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors","volume":"99","author":"Wan","year":"2024","journal-title":"An Bras Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003251107","article-title":"IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis","volume":"107","author":"Teng","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/cells11020259","article-title":"Regression of Triple-Negative Breast Cancer in a Patient-Derived Xenograft Mouse Model by Monoclonal Antibodies against IL-12 p40 Monomer","volume":"11","author":"Kundu","year":"2022","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.12.018","article-title":"Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment","volume":"15","author":"Kortylewski","year":"2009","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04705.x","article-title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis","volume":"27","author":"Langley","year":"2013","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1964420","article-title":"A non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"mAbs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028530","article-title":"Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer","volume":"10","author":"Yan","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1337","article-title":"Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state","volume":"72","author":"Teng","year":"2012","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2010.02.009","article-title":"Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma","volume":"41","author":"Ljujic","year":"2010","journal-title":"Arch Med Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-030-55617-4_6","article-title":"IL-23 and the tumor microenvironment","volume":"1290","author":"Subhadarshani","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad081","article-title":"Safety of guselkumab in patients with psoriasis with a history of Malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials","volume":"189","author":"Blauvelt","year":"2023","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00162","article-title":"IL-23R is epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer","volume":"3","author":"Baird","year":"2013","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1573495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:35Z","timestamp":1750392635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1573495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1573495"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1573495","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1573495"}}